0001179110-20-004830.txt : 20200410 0001179110-20-004830.hdr.sgml : 20200410 20200410173039 ACCESSION NUMBER: 0001179110-20-004830 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200408 FILED AS OF DATE: 20200410 DATE AS OF CHANGE: 20200410 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Veness Adam M CENTRAL INDEX KEY: 0001778623 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 20787555 MAIL ADDRESS: STREET 1: C/O ACCELERON PHARMA INC. STREET 2: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2020-04-08 0 0001280600 ACCELERON PHARMA INC XLRN 0001778623 Veness Adam M 128 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 SVP, General Counsel and Sec. Common Stock 2020-04-08 4 M 0 6000 27.97 A 27161 D Common Stock 2020-04-08 4 S 0 900 83.49 D 26261 D Common Stock 2020-04-08 4 S 0 700 84.62 D 25561 D Common Stock 2020-04-08 4 S 0 2883 85.77 D 22678 D Common Stock 2020-04-08 4 S 0 1100 86.69 D 21578 D Common Stock 2020-04-08 4 S 0 417 87.53 D 21161 D Option to Purchase Common Stock 27.97 2020-04-08 4 M 0 6000 0 D 2026-03-03 Common Stock 6000 0 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.95 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.18 to $85.12 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.30 to $86.11 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.35 to $87.29 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.39 to $87.60 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2016. /s/ Adam M. Veness 2020-04-10